Fig. 2From: Validation of neuromuscular blocking agent use in acute respiratory distress syndrome: a meta-analysis of randomized trialsThe effect of NMBAs on mortality truncated to day 28 (a) and day 90 (b) in moderate-to-severe ARDS patients. a The effect of NMBA on mortality truncated to day 28 in moderate-to-severe ARDS patients. b The effect of NMBA on mortality truncated to day 90 in moderate-to-severe ARDS patientsBack to article page